
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has demonstrated strong revenue growth, with a year-over-year increase of 57% in its core revenue, supported by a higher mix of new prescriptions in the pharmacy channel than anticipated. The company has revised its revenue projections upward for 2025 and 2026, anticipating $97.5 million and $136 million respectively, while also indicating continued enhancements in quarterly revenue estimates due to strong new prescription momentum. Furthermore, management has raised its fiscal year 2025 revenue guidance by over $6 million, reflecting confidence in sustained premium growth, estimated at a compound annual growth rate of 30-40% from 2024 to 2028.
Bears say
Beta Bionics faces several key challenges that contribute to a negative outlook on its stock, primarily related to its flagship iLet Bionic Pancreas product. The company risks failing to secure significant market share and may struggle with sustained penetration into the pharmacy channel, which could adversely affect revenue and profitability projections. Additionally, potential delays in clinical development and regulatory approvals could hinder adoption rates, alongside possible shareholder dilution from capital needs and unfavorable Medicare reimbursement proposals that could further impact the company's financial performance.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares